



PRESS RELEASE

Published: 13-12-2023

Inhalation Sciences' captures interest and interaction at its latest industry webinar 'Inhaled Biologics'

(Stockholm, Sweden, 13 December 2023) **Interest and interaction was high on December 11 at ISAB's latest industry webinar, 'Inhaled Biologics'. Over 200 scientists registered for the event, the latest in ISAB's highly popular series, with attendees logging in from Europe, Asia and the US. The webinar was co-hosted by experts in the formulation and drying of biologics, Ziccum AB.**

On December 11 at 11AM EST ISAB held the latest in its popular series of co-hosted industry webinars. The series has become a regular fixture for many scientists working in inhaled therapeutics and drug development, offering deep dives, Case Studies and novel solutions into a range of challenges and areas.

This webinar, "Inhaled Biologics: Realization and Preclinical Testing of Dry Powder Formulations", presented innovative methods for drying, formulating and testing liquid solution biologics as inhalable dry powders, including a Case Study presented by ISAB CSO Assoc Prof Per Gerde that included PK data from ISAB's advanced specially configured IPL (Isolated Perfused Lung) test module.

The event's co-host was Swedish biotech company Ziccum AB. Ziccum's COO Xavier Turon presented how the company's unique formation and drying technology for biologics, LaminarPace, originally invented by Per Gerde, turns delicate liquid solution biologics into thermostable dry powders highly suited to inhalation.

As ever ISAB's Chief Commercial Officer Paolo Raffaelli, the organizer and host of the industry webinar series, introduced the event and moderated the Q&A.

CEO Manoush Masarrat: "These webinars give experts in the field the chance to discover and dive into new solutions and capabilities that can solve major challenges. They are an excellent technology showcase and a great opportunity for Business Development, networking and knowledge sharing".

Watch the webinar [HERE](#).

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.